Cupid Ltd – the company that manufactures condoms, lubes, and now even COVID test kits – is basically India’s answer to Durex but with the share price volatility of a penny stock. On one hand, it’s guarding the nation’s population control mission, on the other hand, it’s trying to penetrate (pun intended) every product category possible. From glow-in-the-dark jokes to tender contracts, Cupid is always in the mood.
2. Introduction
Picture this: A small-cap company from Nashik that started in 1993 making condoms, supplying UN agencies, exporting to Africa, and suddenly finding itself in headlines for COVID kits during the pandemic. Cupid Ltd has had more makeovers than a Bollywood actor trying to stay relevant across three decades.
While most FMCG brands launch shampoos and soaps, Cupid has diversified from latex balloons for adults to medical kits, deodorants, and even plans to launch intimate hygiene products. If diversification had a Tinder profile, Cupid’s bio would read: “Down for anything, anywhere, anytime.”
Investors meanwhile swipe right hoping they catch the next multi-bagger, but instead often end up with a heartbreak worse than the first college breakup.
3. Business Model (WTF Do They Even Do?)
Cupid Ltd runs on two engines:
Male & Female Condoms: This is the bread, butter, and… let’s say latex of the business. They bag large contracts from international agencies like UNFPA, WHO, USAID and export heavily to Africa, South America, and India’s family planning programmes.
Lubricants & Allied Products: They also sell water-based lubricants, gels, and creams. The margins here are higher – because apparently desire is more profitable than duty.
Medical Diversification: Post-COVID, they even started selling IVD kits and medical disposables. Investors clapped initially, but now ask: “Bhai, are you FMCG, pharma, or population control?”
The problem? The company’s revenues are lumpy, entirely dependent on government and UN tenders. No tender = no love.
4. Financials Overview
Metric
Latest Qtr (Q1 FY26)
YoY Qtr (Q1 FY25)
Prev Qtr (Q4 FY25)
YoY %
QoQ %
Revenue
₹99 Cr
₹112 Cr
₹121 Cr
-11.6%
-18.1%
EBITDA
₹18 Cr
₹23 Cr
₹27 Cr
-21.7%
-33.3%
PAT
₹11 Cr
₹15 Cr
₹19 Cr
-26.6%
-42.1%
EPS (₹)
4.0
5.4
7.2
-26.6%
-44.4%
Commentary: The last quarter looked like a post-party hangover. Sales fell double digits, profits collapsed faster than a cheap tent. If you annualise EPS at ₹16, the stock trades at ~26x earnings. For a condom company? That’s a pretty stretched elastic.
5. Valuation (Fair Value Range)
We run 3 methods (all educational, not advice):
P/E Method: EPS (₹16) × reasonable range (18–22x) = ₹288–₹352.
EV/EBITDA Method: EBITDA ~₹80 Cr annual. Apply 9–11x = EV ₹720–₹880 Cr. Adjust for cash/debt → Equity Value = ₹310–₹380/share.
DCF Method: Assuming 10% CAGR revenue growth (optimistic, given tender-based), discount at 12%, FV ~₹300/share.
👉 Fair Value Range: ₹288–₹380. “This FV range is for educational purposes only and is not investment advice.”
6. What’s Cooking – News, Triggers, Drama
New Tender Wins: Cupid’s lifeline is bagging UN or Govt. tenders. Every big order is like an arranged marriage proposal – exciting, but unpredictable.
New Product Launches: They’re expanding into female hygiene gels, deodorants, and “lifestyle intimacy” products. Basically, trying to become India’s Durex.
Export Opportunities: African demand is steady. But dependence on one geography = risky.
Cupid keeps getting speculative retail attention because – well, condoms are always a hot topic.
Trigger question: Should Cupid stick to its latex roots or keep diversifying into every adjacent product possible?
